Taken together, these findings suggest that GIP at pharmacological concentrations could exert protective effects against atherosclerosis without deteriorating the obesity, and the beneficial effects of GIP might also be preserved in diabetic animals. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.